Docetaxel-based therapy for lung cancer
Author Information
Author(s): Scagliotti G V, Szczesna A, Ramlau R, Cardenal F, Mattson K, Van Zandwijk N, Price A, Lebeau B, Debus J, Manegold C
Primary Institution: University of Torino, S Luigi Hospital
Hypothesis
Can docetaxel-based induction therapy improve outcomes in patients with locally advanced non-small-cell lung cancer (NSCLC) when followed by radiotherapy?
Conclusion
Docetaxel and cisplatin induction therapy followed by concurrent docetaxel and thoracic radiotherapy is a feasible treatment option for locally advanced NSCLC, showing good clinical activity and tolerability.
Supporting Evidence
- Overall response rate after induction chemotherapy was 44%.
- After randomised therapy, the overall response rate was 53%.
- The median survival was 14.9 months for chemoradiotherapy and 14.0 months for radiotherapy alone.
Takeaway
This study tested a new way to treat lung cancer using a combination of drugs and radiation, and it found that this method can help many patients feel better.
Methodology
Patients received two cycles of docetaxel and cisplatin, followed by randomization to either radiotherapy alone or with additional docetaxel.
Limitations
The results were not compelling enough to justify a phase III study.
Participant Demographics
{"median_age":59,"gender_distribution":{"male":84,"female":24},"performance_status":{"0":21,"1":87},"histology":{"adenocarcinoma":36,"large_cell_carcinoma":7,"squamous_cell_carcinoma":47,"other":18},"disease_stage":{"IIIA":27,"IIIB":81}}
Statistical Information
Confidence Interval
{"overall_survival":"95% CI: 11.20–16.20 months","median_survival_chemoradiotherapy":"95% CI: 10.02–22.21 months","median_survival_radiotherapy":"95% CI: 11.10–15.67 months","median_time_to_progression":"95% CI: 7.03–9.43 months"}
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website